Notice: This company has been marked as potentially delisted and may not be actively trading. Vascular Biogenics (VBLT) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Market Unimpressed By VBL's 26% Jump In Net Profit, Shares Tank 5%July 30, 2024 | msn.comVBL Shares Climb As Q1 Profits Soar 25%: Why Analysts Think There's More To ComeMay 14, 2024 | msn.comVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26November 3, 2023 | msn.comNotable Labs Closes Merger Transaction With VBL TherapeuticsOctober 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Results of Annual and Special Shareholder MeetingOctober 12, 2023 | finance.yahoo.comVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder MeetingOctober 4, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeSeptember 9, 2023 | finance.yahoo.comVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECSeptember 6, 2023 | finance.yahoo.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comVascular Biogenics (NASDAQ: VBLT)July 23, 2023 | fool.comVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 15, 2023 | finance.yahoo.comVascular Biogenics Stock (NASDAQ:VBLT), DividendsApril 4, 2023 | benzinga.comVascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)March 17, 2023 | finance.yahoo.comVBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 14, 2023 | finance.yahoo.comVBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in CashMarch 9, 2023 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLTFebruary 27, 2023 | prnewswire.comVBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to ShareholdersFebruary 23, 2023 | technews.tmcnet.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. MergerFebruary 23, 2023 | benzinga.comVascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLTFebruary 23, 2023 | marketwatch.comVascular Biogenics rises 85% on all-stock merger deal with Notable LabsFebruary 23, 2023 | msn.comWhy Is Vascular Biogenics (VBLT) Stock Up 52%?February 23, 2023 | investorplace.comTrading was temporarily halted for "VBLT" at 06:02 AM with a stated reason of "News pending."February 23, 2023 | marketbeat.comVBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in CashFebruary 16, 2023 | finance.yahoo.comOYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue EstimatesNovember 10, 2022 | finance.yahoo.comAxsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07September 2, 2022 | finance.yahoo.comVBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencySeptember 1, 2022 | finance.yahoo.comSorrento (SRNE) Gets FDA Fast Track Tag for Back Pain ProductSeptember 1, 2022 | finance.yahoo.comVascular Biogenics Cutting About 35% of Staff >VBLTAugust 2, 2022 | marketwatch.comVBL Therapeutics Announces Workforce ReductionAugust 2, 2022 | finance.yahoo.comVascular Biogenics (VBLT) Down, Ovarian Cancer Study FailsJuly 21, 2022 | finance.yahoo.comGold Prices Settle Lower; Vascular Biogenics Shares PlummetJuly 20, 2022 | msn.comWhy Is Vascular Biogenics (VBLT) Stock Down 80% Today?July 20, 2022 | msn.comRead Why VBL Therapeutics Shares Are Falling To a 52-Week LowJuly 20, 2022 | finance.yahoo.comVBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian CancerJuly 19, 2022 | finance.yahoo.comTrading was temporarily halted for "VBLT" at 04:07 PM with a stated reason of "News pending."July 19, 2022 | marketbeat.comVascular Biogenics (NASDAQ:VBLT) Given "Outperform" Rating at OppenheimerOppenheimer reissued an "outperform" rating and set a $5.50 price objective on shares of Vascular Biogenics in a report on Monday.July 18, 2022 | marketbeat.comShort Interest in Vascular Biogenics Ltd. (NASDAQ:VBLT) Declines By 22.4%Vascular Biogenics Ltd. (NASDAQ:VBLT - Get Rating) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 328,700 shares, a decline of 22.4% from the May 31st total of 423,700 shares. Based on an average daily volume of 163,400 shares, the days-to-cover ratio is currently 2.0 days. Currently, 0.7% of the shares of the stock are sold short.July 4, 2022 | marketbeat.comVascular Biogenics (NASDAQ:VBLT) Upgraded by Zacks Investment Research to HoldZacks Investment Research raised shares of Vascular Biogenics from a "sell" rating to a "hold" rating in a research note on Friday.June 10, 2022 | marketbeat.comVBL Therapeutics to Participate in the Jefferies Healthcare ConferenceMay 31, 2022 | finance.yahoo.comQ2 2022 EPS Estimates for Vascular Biogenics Ltd. (NASDAQ:VBLT) Decreased by OppenheimerVascular Biogenics Ltd. (NASDAQ:VBLT - Get Rating) - Equities research analysts at Oppenheimer lowered their Q2 2022 EPS estimates for Vascular Biogenics in a report issued on Tuesday, May 17th. Oppenheimer analyst K. Degeeter now forecasts that the biopharmaceutical company will post earnings ofMay 20, 2022 | marketbeat.comOppenheimer Comments on Vascular Biogenics Ltd.'s Q1 2023 Earnings (NASDAQ:VBLT)Vascular Biogenics Ltd. (NASDAQ:VBLT - Get Rating) - Equities researchers at Oppenheimer issued their Q1 2023 earnings per share (EPS) estimates for shares of Vascular Biogenics in a report issued on Tuesday, May 17th. Oppenheimer analyst K. Degeeter expects that the biopharmaceutical company wilMay 19, 2022 | marketbeat.comVBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMay 17, 2022 | stockhouse.comVBL Therapeutics to Report First Quarter 2022 Financial Results on May 17May 10, 2022 | finance.yahoo.comWhat Kind Of Shareholders Hold The Majority In Vascular Biogenics Ltd.'s (NASDAQ:VBLT) Shares?May 8, 2022 | finance.yahoo.comVBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in MayMay 3, 2022 | finance.yahoo.comVascular Biogenics (NASDAQ:VBLT) Now Covered by Analysts at Chardan CapitalChardan Capital assumed coverage on Vascular Biogenics in a research report on Thursday. They set a "buy" rating and a $5.00 target price on the stock.April 28, 2022 | marketbeat.comThe Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell ...April 26, 2022 | msn.comVascular Biogenics (VBLT) Presents at the KOL Event on Ovarian Cancer - SlideshowApril 16, 2022 | seekingalpha.com Get Vascular Biogenics News Delivered to You Automatically Sign up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. Email Address VBLT Media Mentions By Week VBLT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VBLT News Sentiment▼0.000.78▲Average Medical News Sentiment VBLT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VBLT Articles This Week▼00▲VBLT Articles Average Week Get Vascular Biogenics News Delivered to You Automatically Sign up to receive the latest news and ratings for VBLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MNKD News DVAX News GLPG News ARQT News INDV News AKRO News DYN News EVO News TVTX News GPCR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VBLT) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vascular Biogenics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vascular Biogenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
